Kuhnil Pharmaceutical

Dyslipidemia combination that puts rosuvastatin and omega-3 in one capsule using a patented multi-layer capsule coating; co-promoted with Youngjin Pharm since May 2025.

Melatonin treatment for sleep disorders in children and adolescents; a 3 mm mini-tablet with patented prolonged-release technology keeps melatonin levels for 8 to 10 hours after bedtime. In July 2026 its indication was extended from autism spectrum disorder to ADHD-related sleep disorders.

Prolonged-release melatonin 2 mg tablet developed by Israel's Neurim Pharmaceuticals for primary insomnia in patients aged 55 and over; imported since 2014, it moved to in-house production after a domestic manufacturing approval in July 2026.

Inhaled budesonide suspension for bronchial asthma and acute bronchitis in young children; the company has expanded production equipment fourfold from 2024 and also manufactures versions for other drugmakers under contract.

Affiliate that launched its self-produced asthma treatment Pulmicure in May 2025.

Expanded production equipment for the inhaled budesonide Pulmican fourfold from 2024 and took on contract manufacturing for products of five drugmakers, including those of Youngjin Pharm and Penmix.

Renewed the Rosumega co-promotion agreement with Youngjin Pharm for two years; the first one-year agreement was signed in May 2025.

Received a domestic manufacturing approval for Circadin prolonged-release 2 mg tablets and withdrew the import approval held since 2014, moving to in-house production.

Extended Slenyto's indication from sleep disorders linked to autism spectrum disorder to sleep disorders in children and adolescents with ADHD; the company says it is the only treatment approved for this use in Korea.